T1	Participants 689 844	The single and combination groups comprised 14 and 13 patients, respectively, and there was no significant difference between the background of both groups
T2	Participants 1727 1786	remission induction chemotherapy for acute myeloid leukemia
T3	Participants 69 165	nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia
